Maria Chiara Lo Greco

Dr. Maria Chiara Lo Greco

Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali, University of Messina, Messina, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
EDEmanuele David
Emanuele David
HGHektor Grazhdani
Hektor Grazhdani
GTGiuliana Tattaresu
Giuliana Tattaresu
APAlessandra Pittari
Alessandra Pittari
PFPietro Valerio Foti
Pietro Valerio Foti
BABasile Antonio
Basile Antonio
Ultrasound (US) is the primary tool for evaluating patients with thyroid nodules, and the risk of malignancy assessed is based on US features. These features help determine which patients require fine-needle aspiration (FNA) biopsy. Classification systems for US features have been developed to facilitate efficient interpretation, reporting, and communication of thyroid US findings. These systems have been validated by numerous studies and are reviewed in this article. Additionally, this overview provides a comprehensive description of the clinical and laboratory evaluation of patients with thyroid nodules, various imaging modalities, grayscale US features, color Doppler US, contrast-enhanced US (CEUS), US elastography, FNA biopsy assessment, and the recent introduction of molecular testing. The potential of artificial intelligence in thyroid US is also discussed.

1 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MGMaria Chiara Lo Greco
Maria Chiara Lo Greco
MRMadalina La Rocca
Madalina La Rocca
GMGiorgia Marano
Giorgia Marano
IFIrene Finocchiaro
Irene Finocchiaro
RLRocco Luca Emanuele Liardo
Rocco Luca Emanuele Liardo
CSCorrado Spatola
Corrado Spatola
While surgery is considered the main treatment for early-stage rectal cancer, locally advanced rectal cancer needs to be handled with a multidisciplinary approach. Based on literature data suggesting promising advantages of total neoadjuvant therapy (TNT), we performed a retrospective, single-arm, single-center study on 45 patients affected by histologically and radiologically proven locally advanced rectal cancer, with the aim of analyzing the feasibility and short-term efficacy of an integrated intensified treatment in the setting of TNT. Each analyzed patient performed three cycles of FOLFOX4 or De Gramont induction chemotherapy (iCT), followed by concurrent chemoradiotherapy (CRT) with long course radiotherapy (LCRT) plus concomitant boost and continuous 5-FU infusion, followed by three cycles of FOLFOX4 or De Gramont consolidation chemotherapy (conCT) and then surgery with total mesorectal excision. At a median follow-up of 30 months, this strategy has shown to be feasible and effective in terms of pathological complete response (pCR) and short-term disease-free survival (DFS).

22 March 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MGMaria Chiara Lo Greco
Maria Chiara Lo Greco
RMRoberto Milazzotto
Roberto Milazzotto
RLRocco Luca Emanuele Liardo
Rocco Luca Emanuele Liardo
GAGrazia Acquaviva
Grazia Acquaviva
MRMadalina La Rocca
Madalina La Rocca
CSCorrado Spatola
Corrado Spatola
Glioblastoma (GBM) is the most common and aggressive brain tumor in adults, with a median survival of about 15 months. After the prior treatment, GBM tends to relapse within the high dose radiation field, defined as the peritumoral brain zone (PTZ), needing a second treatment. In the present review, the primary role of ionizing radiation in recurrent GBM is discussed, and the current literature knowledge about the different radiation modalities, doses and fractionation options at our disposal is summarized. Therefore, the focus is on the necessity of tailoring the treatment approach to every single patient and using radiomics and PET/MRI imaging to have a relatively good outcome and avoid severe toxicity. The use of charged particle therapy and radiosensitizers to overcome GBM radioresistance is considered, even if further studies are necessary to evaluate the effectiveness in the setting of reirradiation.

10 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MRMadalina La Rocca
Madalina La Rocca
BLBarbara Francesca Leonardi
Barbara Francesca Leonardi
MGMaria Chiara Lo Greco
Maria Chiara Lo Greco
GMGiorgia Marano
Giorgia Marano
IFIrene Finocchiaro
Irene Finocchiaro
CSCorrado Spatola
Corrado Spatola
Orbital and ocular adnexa lymphomas are rare neoplasms confined to the orbital region. The prognosis is generally favorable, with a high proportion of localized disease, indolent clinical course, prolonged disease-free intervals, and low lymphoma-related mortality rate. We report our experience on eleven patients with confirmed histological diagnosis of lymphoma stage IE-IIE, treated between 2010 and 2021 with radiotherapy alone or in association with chemotherapy or immunotherapy. Eight patients were treated with primary radiotherapy only, while three received previous systemic treatments. Six patients were treated with Proton beam therapy (PBT), and five with external beam radiotherapy (EBRT). The five-year local control rate was 98%; only one patient developed an out-of-field recurrence. We also conducted a comprehensive literature review using electronic databases (PubMed, EMBASE, and Cochrane Library). Articles were selected based on their pertinence to treatment of the ocular and adnexal lymphoma focusing on radiotherapy techniques (electron beam radiotherapy, photon beam radiotherapy, or proton beam radiotherapy), treatment total dose, fractionation schedule, early and late radio-induced toxicities, and patient’s clinical outcome. Radiotherapy is an effective treatment option for orbital lymphoma, especially as standard treatment in the early stage of orbital lymphoma, with excellent local control rate and low rates of toxicity.

27 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MGMaria Chiara Lo Greco
Maria Chiara Lo Greco
GMGiorgia Marano
Giorgia Marano
MRMadalina La Rocca
Madalina La Rocca
GAGrazia Acquaviva
Grazia Acquaviva
RMRoberto Milazzotto
Roberto Milazzotto
CSCorrado Spatola
Corrado Spatola
Despite recent advancements in radiotherapy for Diffuse Intrinsic Pontine Glioma (DIPG), the prognosis of this disease remains poor, highlighting the need for new treatment strategies to improve outcomes. Adding stereotactic biopsy to the diagnostic process for children with DIPG has been crucial in improving the management of this disease. Indeed, the discovery of the H3K27M mutation as a key driver of DIPG has led to the development of new drugs that are more effective than traditional ones. These include nimotuzumab (an anti-EGFR drug) and vinorelbine (a semisynthetic vinca alkaloid) in combination, Panobinostat (a histone deacetylase inhibitor), ONC201 (a drug that blocks the dopamine receptor D2 and inactivates Akt and ERK kinases), and chimeric antigen receptor (CAR) T cells. In terms of local therapy, identifying the H3K27M mutation can help us explore how genetic changes affect treatment response, recurrence patterns, and survival. Beyond the time to first recurrence, specific patterns of tumor recurrence, like leptomeningeal spread, can influence treatment plans. For example, radiotherapy can be adjusted in terms of doses and volumes, based on tumor aggressiveness. Because the H3K27M mutation is linked to higher malignancy, a slightly higher dose could be used for the second round of local irradiation. Additionally, irradiating the entire craniospinal axis could help control both local and leptomeningeal disease.

11 October 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MGMaria Chiara Lo Greco
Maria Chiara Lo Greco
RMRoberto Milazzotto
Roberto Milazzotto
RLRocco Luca Emanuele Liardo
Rocco Luca Emanuele Liardo
PFPietro Valerio Foti
Pietro Valerio Foti
Stefano PalmucciStefano Palmucci
Stefano Palmucci
CSCorrado Spatola
Corrado Spatola
To investigate the clinical impact of multiple courses of irradiation on pediatric patients with progressive diffuse intrinsic pontine glioma (DIPG), we conducted a retrospective case series on three children treated at our institution from 2018 to 2022. All children were candidates to receive systemic therapy with vinorelbine and nimotuzumab. Radiotherapy was administered to a total dose of 54 Gy. At any disease progression, our local tumor board evaluated the possibility of offering a new course of radiotherapy. To determine feasibility and assess toxicity rates, all children underwent clinical and hematological evaluation both during and after the treatment. To assess efficacy, all children performed contrast-enhanced MRI almost quarterly after the end of the treatment. In all children, following any treatment course, neurological improvement (>80%) was associated with a radiological response (41.7–46%). The longest overall survival (24 months) was observed in the child who underwent three courses of radiotherapy, without experiencing significant side effects. Even though it goes beyond the understanding of conventional radiobiology, first and second reirradiation in pediatric patients with progressive DIPG may represent a feasible and safe approach, capable of increasing overall survival and disease-free survival in selected patients and improving their quality of life.